Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous menstrual blood stromal stem cells (MenSCs) are a population of mesenchymal stem cells (MSCs) isolated from a patient's own menstrual blood. These cells exhibit high proliferative capacity, multi-lineage differentiation potential, and low immunogenicity. In the context of reproductive medicine, MenSCs are being investigated for their ability to promote endometrial regeneration and repair in patients with severe endometrial injury or Asherman's syndrome. The therapeutic effect is primarily mediated through paracrine signaling, where the cells secrete various growth factors (such as VEGF and TGF-β) and cytokines that stimulate angiogenesis, reduce fibrosis, and enhance the proliferation of resident endometrial cells, thereby improving uterine receptivity and fertility outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous menstrual blood stromal stem cells.